MINNEAPOLIS, May 20, 2015 (GLOBE NEWSWIRE) -- BioSig Technologies (OTCQB:BSGM), a medical device company developing PURE EP(TM) a proprietary technology platform designed to improve the clarity of clinical signals available for electrophysiology (EP) procedures, today announced that it will be present at the 2015 Marcum MicroCap Conference on Wednesday and Thursday, May 27-28, 2015 in New York City at the Grand Hyatt Hotel.
The Company's presentation by Kenneth Londoner, Executive Chairman and Greg Cash, Chief Executive Officer is scheduled to begin at 1:00 p.m. ET on Wednesday, May 27 in the Edison and will be available via a live webcast. To access the webcast, go to http://wsw.com/webcast/marcum3/bsgm/.
BioSig Technologies' presentation will focus on informing investors about its leading technology, the PURE EP™ System, which is designed to provide real-time, high clarity cardiac recordings that can be used by electrophysiologists to aide in accurate and efficient diagnostic EP studies and catheter ablation treatments.
The annual Marcum MicroCap Conference is a showcase for public companies with less than $500 million in market capitalization.
"It is exciting to present at the Third Annual Marcum MicroCap Conference for the first time as a public company," said Kenneth Londoner, Executive Chairman of BioSig Technologies. "We look forward to meeting investors interested in learning about our young and growing enterprise."
For more information or to register, please visit the conference website at http://www.marcumllp.com/microcap or download the free official conference app for the iPhone, iPad, or for Android mobile devices in Apple's App Store and the Google Play Market.
About BioSig Technologies
BioSig is a medical device company that has developed a proprietary technology platform designed to greatly improve the $3 billion electrophysiology (EP) marketplace(1) (www.biosigtech.com). Led by a proven management team and a veteran, independent Board of Directors, Minneapolis-based BioSig is preparing to commercialize its PURE EP System.
PURE EP is a next-generation surface electrocardiogram and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings and providing clarity of data which may be used to guide the EP's in identifying ablation targets - areas of tissue to destroy that otherwise create a heart rhythm disturbance (arrhythmia).
Analysts forecast the global market for EP devices will grow at a 12.1 percent compound annual growth rate, from $2.5 billion in 2012 to $5.5 billion by 2019(1) - making it one of the fastest growing medical device segments. Just in the US, the number of Atrial Fibrillation (AF) and Ventricular Tachycardia (VT) arrhythmia ablations is forecast to grow at 10.5 percent from 2012 to 2017(2).
BioSig intends to seek FDA 510(k) clearance for the PURE EP System. The Company has already achieved proof of concept validation through UCLA EP & Animal Labs and has performed preclinical studies at the Mayo Clinic in Minnesota. BioSig is collaborating with several of the nation's most prestigious cardiac arrhythmia centers including Texas Cardiac Arrhythmia Institute, UCLA Cardiac Arrhythmia Center, and Mayo Clinic.
About the Marcum MicroCap Conference
The Marcum MicroCap Conference is dedicated to providing a forum where publicly traded companies under $500 million in market capitalization can network with the investment community. The conference features presentations by CEOs and CFOs from six principal industry sectors and provides investors with the opportunity to meet with management of these companies on a one-on-one basis. Industry sectors include Technology, Media & Internet; Software & Business Services; Life Science & Healthcare; Retail & Consumer Products; Energy & Natural Resources; and Industrials. The conference additionally includes a full agenda of panel discussions on issues of strategic importance to small cap issuers and investors, moderated by industry leaders.
The Marcum MicroCap Conference attracts fund managers and high net worth investors focusing on small cap equities. Over 2,000 participants from all segments of the microcap market attend each year, including senior management, finance and legal executives, venture and lower middle-market private equity investors, institutional investors, directors, investment bankers, buy- and sell-side analysts, and service providers to the microcap marketplace.
For complete information about the 2015 Marcum MicroCap Conference, visit www.marcumllp.com/microcap.
Marcum is a registered Public Company Accounting Oversight Board (PCAOB) firm. Marcum's Assurance Division provides the most up-to-date service and guidance on SEC accounting and reporting issues. Services include Financial Statement Audits in accordance with PCAOB standards; Tax Compliance and Advisory Services; Due Diligence; Agreed-Upon Procedures and Other Attest Work; Internal Audit Services; Sarbanes-Oxley Section 404 Compliance Services and Software; Technical Accounting Assistance; and IPO Assistance. Marcum's SEC Practice led the audit industry in most net new public company clients in the fourth quarter of 2013. For more information, visit www.marcumllp.com.
About Marcum LLP
Marcum LLP is one of the largest independent public accounting and advisory services firms in the United States. Ranked #15 nationally, Marcum LLP offers the resources of 1,300 professionals, including over 160 partners, in 23 offices throughout the U.S., Grand Cayman and China. Headquartered in New York City, the Firm's presence runs deep, with full-service offices strategically located in major business markets. Marcum is a member of the Marcum Group, an organization providing a comprehensive range of professional services spanning accounting and advisory, technology solutions, wealth management, and executive and professional recruiting. The Marcum Group companies include Marcum LLP; Marcum Technology LLC; Marcum Search LLC; Marcum Financial Services LLC; Marcum Bernstein & Pinchuk LLP; and MarcumBuchanan Associates LLC.
This release includes forward-looking statements. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing, regulatory approvals, competition and marketplace demand. More information, and BioSig risk factors, are set forth in its filings with the SEC. BioSig assumes no obligation to publicly update or revise its forward-looking statements.
(1) Electrophysiology Devices Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019
(2) HRI 2013 "Global Opportunities in Medical Devices & Diagnostics" report; triangulation of multiple sources; *AF includes left atrial tachycardia, left WPW, left atrial flutter.
Source:BioSig Technologies, Inc.